KR20110081341A - 증가된 인터페론 감마를 생산하는 활성화된 항원 특이적 ｔ 세포를 포함하는 조성물 - Google Patents
증가된 인터페론 감마를 생산하는 활성화된 항원 특이적 ｔ 세포를 포함하는 조성물 Download PDFInfo
- Publication number
- KR20110081341A KR20110081341A KR1020117012621A KR20117012621A KR20110081341A KR 20110081341 A KR20110081341 A KR 20110081341A KR 1020117012621 A KR1020117012621 A KR 1020117012621A KR 20117012621 A KR20117012621 A KR 20117012621A KR 20110081341 A KR20110081341 A KR 20110081341A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- bcg
- dendritic cells
- antigen
- ifnγ
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 116
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 230000001965 increasing effect Effects 0.000 title claims description 17
- 102000008070 Interferon-gamma Human genes 0.000 title claims description 13
- 108010074328 Interferon-gamma Proteins 0.000 title claims description 13
- 229960003130 interferon gamma Drugs 0.000 title claims description 13
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 255
- 230000035800 maturation Effects 0.000 claims abstract description 62
- 239000000427 antigen Substances 0.000 claims description 142
- 108091007433 antigens Proteins 0.000 claims description 142
- 102000036639 antigens Human genes 0.000 claims description 142
- 230000004913 activation Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 90
- 238000000034 method Methods 0.000 abstract description 31
- 102000004127 Cytokines Human genes 0.000 abstract description 30
- 108090000695 Cytokines Proteins 0.000 abstract description 30
- 230000004044 response Effects 0.000 abstract description 26
- 238000004519 manufacturing process Methods 0.000 abstract description 22
- 230000028993 immune response Effects 0.000 abstract description 9
- 230000037452 priming Effects 0.000 abstract description 7
- 230000001939 inductive effect Effects 0.000 abstract description 5
- 230000003213 activating effect Effects 0.000 abstract description 3
- 239000002243 precursor Substances 0.000 description 52
- 108010065805 Interleukin-12 Proteins 0.000 description 47
- 102000013462 Interleukin-12 Human genes 0.000 description 47
- 102000003814 Interleukin-10 Human genes 0.000 description 44
- 108090000174 Interleukin-10 Proteins 0.000 description 44
- 229940076144 interleukin-10 Drugs 0.000 description 44
- 229940117681 interleukin-12 Drugs 0.000 description 38
- 102000004388 Interleukin-4 Human genes 0.000 description 25
- 108090000978 Interleukin-4 Proteins 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 25
- 229940028885 interleukin-4 Drugs 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 19
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 17
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 17
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 16
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 13
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 13
- 210000000265 leukocyte Anatomy 0.000 description 13
- 210000001616 monocyte Anatomy 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- 230000016396 cytokine production Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000005867 T cell response Effects 0.000 description 10
- 230000004069 differentiation Effects 0.000 description 10
- 230000003308 immunostimulating effect Effects 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000031261 interleukin-10 production Effects 0.000 description 9
- 230000019734 interleukin-12 production Effects 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 102000003816 Interleukin-13 Human genes 0.000 description 8
- 108090000176 Interleukin-13 Proteins 0.000 description 8
- 239000013592 cell lysate Substances 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 239000012452 mother liquor Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000003104 tissue culture media Substances 0.000 description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 102000054766 genetic haplotypes Human genes 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 206010022000 influenza Diseases 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- 102100035793 CD83 antigen Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 4
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 4
- 241000712431 Influenza A virus Species 0.000 description 4
- 102000003812 Interleukin-15 Human genes 0.000 description 4
- 108090000172 Interleukin-15 Proteins 0.000 description 4
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- -1 AIM-V Substances 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- 238000002617 apheresis Methods 0.000 description 3
- 230000003416 augmentation Effects 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000004041 dendritic cell maturation Effects 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 210000001821 langerhans cell Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- VHVVPYOJIIQCKS-QEJZJMRPSA-N Ala-Leu-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VHVVPYOJIIQCKS-QEJZJMRPSA-N 0.000 description 2
- KQBVNNAPIURMPD-PEFMBERDSA-N Asp-Ile-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O KQBVNNAPIURMPD-PEFMBERDSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- KYIIALJHAOIAHF-KKUMJFAQSA-N Leu-Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 KYIIALJHAOIAHF-KKUMJFAQSA-N 0.000 description 2
- 241000186366 Mycobacterium bovis Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- HBZBPFLJNDXRAY-FXQIFTODSA-N Ser-Ala-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O HBZBPFLJNDXRAY-FXQIFTODSA-N 0.000 description 2
- PMCMLDNPAZUYGI-DCAQKATOSA-N Ser-Lys-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PMCMLDNPAZUYGI-DCAQKATOSA-N 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 108010061181 influenza matrix peptide (58-66) Proteins 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 239000011236 particulate material Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- VOUSELYGTNGEPB-NUMRIWBASA-N Gln-Thr-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O VOUSELYGTNGEPB-NUMRIWBASA-N 0.000 description 1
- BDISFWMLMNBTGP-NUMRIWBASA-N Glu-Thr-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O BDISFWMLMNBTGP-NUMRIWBASA-N 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000007816 calorimetric assay Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 210000004544 dc2 Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000046689 human FOLH1 Human genes 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/72—Undefined extracts from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31759201P | 2001-09-06 | 2001-09-06 | |
| US60/317,569 | 2001-09-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047003386A Division KR20050027163A (ko) | 2001-09-06 | 2002-09-06 | Ｔｈ-1 반응을 위한 단구성 수지상 세포 및 Ｔ 세포를프라이밍하기 위한 조성물 및 방법 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147023675A Division KR101803702B1 (ko) | 2001-09-06 | 2002-09-06 | Ｔｈ-1 반응을 위한 단구성 수지상 세포 및 Ｔ 세포를 프라이밍하기 위한 조성물 및 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20110081341A true KR20110081341A (ko) | 2011-07-13 |
Family
ID=32654226
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117012621A Ceased KR20110081341A (ko) | 2001-09-06 | 2002-09-06 | 증가된 인터페론 감마를 생산하는 활성화된 항원 특이적 ｔ 세포를 포함하는 조성물 |
| KR1020047003386A Ceased KR20050027163A (ko) | 2001-09-06 | 2002-09-06 | Ｔｈ-1 반응을 위한 단구성 수지상 세포 및 Ｔ 세포를프라이밍하기 위한 조성물 및 방법 |
| KR1020147023675A Expired - Lifetime KR101803702B1 (ko) | 2001-09-06 | 2002-09-06 | Ｔｈ-1 반응을 위한 단구성 수지상 세포 및 Ｔ 세포를 프라이밍하기 위한 조성물 및 방법 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047003386A Ceased KR20050027163A (ko) | 2001-09-06 | 2002-09-06 | Ｔｈ-1 반응을 위한 단구성 수지상 세포 및 Ｔ 세포를프라이밍하기 위한 조성물 및 방법 |
| KR1020147023675A Expired - Lifetime KR101803702B1 (ko) | 2001-09-06 | 2002-09-06 | Ｔｈ-1 반응을 위한 단구성 수지상 세포 및 Ｔ 세포를 프라이밍하기 위한 조성물 및 방법 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20050059151A1 (enExample) |
| EP (3) | EP2322603B1 (enExample) |
| JP (3) | JP2005505270A (enExample) |
| KR (3) | KR20110081341A (enExample) |
| CN (2) | CN102973928B (enExample) |
| AU (1) | AU2008221592B2 (enExample) |
| BR (1) | BRPI0212545B8 (enExample) |
| CA (1) | CA2459713C (enExample) |
| DK (2) | DK2322603T3 (enExample) |
| ES (2) | ES2766299T3 (enExample) |
| IL (3) | IL160720A0 (enExample) |
| MX (1) | MXPA04002147A (enExample) |
| NO (2) | NO338147B1 (enExample) |
| NZ (1) | NZ531530A (enExample) |
| PL (1) | PL372098A1 (enExample) |
| PT (2) | PT1441591T (enExample) |
| WO (1) | WO2003022215A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT412145B (de) * | 2002-09-13 | 2004-10-25 | Forsch Krebskranke Kinder | Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen |
| US20040057935A1 (en) * | 2002-09-20 | 2004-03-25 | Cedars-Sinai Medical Center | Intratumoral delivery of dendritic cells |
| WO2004053072A2 (en) * | 2002-12-06 | 2004-06-24 | Northwest Biotherapeutics, Inc. | Administration of dendritic cells partially matured in vitro for the treatment of tumors |
| DK1604016T3 (da) * | 2003-02-27 | 2009-05-18 | Northwest Biotherapeutics Inc | In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler |
| EP1484064A1 (en) | 2003-06-04 | 2004-12-08 | Gesellschaft für Biotechnologische Forschung | Therapeutical composition containing dentritic cells and use thereof |
| EP1670513B1 (en) * | 2003-10-06 | 2013-01-23 | Cedars-Sinai Medical Center | Cox-2 inhibitors and dendritic cells for use in the treatment of cancer. |
| WO2005043155A1 (en) * | 2003-10-21 | 2005-05-12 | Cedars-Sinai Medical Center | System and method for the treatment of cancer, including cancers of the central nervous system |
| JPWO2005042737A1 (ja) * | 2003-11-04 | 2007-05-10 | 株式会社ディナベック研究所 | 遺伝子導入された樹状細胞の製造方法 |
| CA2571849A1 (en) | 2004-06-24 | 2006-01-05 | Dnavec Research Inc. | Anticancer agent containing dendritic cell having rna virus transferred thereinto |
| KR20150082688A (ko) * | 2005-12-08 | 2015-07-15 | 노쓰웨스트 바이오써라퓨틱스, 인크. | 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법 |
| EP1840206A1 (en) * | 2006-03-28 | 2007-10-03 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Compositions for the preparation of mature dendritic cells |
| CA2700573C (en) * | 2006-09-26 | 2016-11-22 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
| WO2008039974A2 (en) | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| ES2565779T3 (es) * | 2008-09-02 | 2016-04-06 | Cedars-Sinai Medical Center | Epítopos CD133 |
| WO2010129895A2 (en) * | 2009-05-07 | 2010-11-11 | Immunocellular Therapeutics, Ltd. | Cd133 epitopes |
| CN104540937A (zh) * | 2012-02-02 | 2015-04-22 | 新干细胞肿瘤学有限责任公司 | 多能胚层起源抗原呈递癌症疫苗 |
| CN104379730B (zh) * | 2012-05-31 | 2016-12-14 | Jw可瑞基因株式会社 | 使树突细胞成熟的组合物以及用其制备抗原特异性树突细胞的方法 |
| US20140065173A1 (en) * | 2012-09-06 | 2014-03-06 | Orbis Health Solutions Llc | Tumor lysate loaded particles |
| AU2020203845C1 (en) * | 2012-09-06 | 2022-08-11 | Orbis Health Solutions, Llc | Tumor lysate loaded particles |
| CA2891602C (en) | 2012-12-12 | 2017-10-24 | Orbis Health Solutions, Llc | Composition comprising an orthosilicate and its use for tissue regeneration |
| US10137182B2 (en) | 2013-02-14 | 2018-11-27 | Immunocellular Therapeutics, Ltd. | Cancer vaccines and vaccination methods |
| CN104936612B (zh) * | 2013-09-05 | 2021-01-01 | 奥比思健康解决方案有限责任公司 | 装载了肿瘤裂解物的微粒 |
| CA2941633C (en) | 2014-03-05 | 2021-01-12 | Orbis Health Solutions Llc | Vaccine delivery systems using yeast cell wall particles |
| US9767516B1 (en) | 2014-05-20 | 2017-09-19 | State Farm Mutual Automobile Insurance Company | Driver feedback alerts based upon monitoring use of autonomous vehicle |
| US11669090B2 (en) | 2014-05-20 | 2023-06-06 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle operation feature monitoring and evaluation of effectiveness |
| US10599155B1 (en) | 2014-05-20 | 2020-03-24 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle operation feature monitoring and evaluation of effectiveness |
| US10373259B1 (en) | 2014-05-20 | 2019-08-06 | State Farm Mutual Automobile Insurance Company | Fully autonomous vehicle insurance pricing |
| US9972054B1 (en) | 2014-05-20 | 2018-05-15 | State Farm Mutual Automobile Insurance Company | Accident fault determination for autonomous vehicles |
| US9783159B1 (en) | 2014-07-21 | 2017-10-10 | State Farm Mutual Automobile Insurance Company | Methods of theft prevention or mitigation |
| US10831204B1 (en) | 2014-11-13 | 2020-11-10 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle automatic parking |
| CN114774356A (zh) * | 2015-06-30 | 2022-07-22 | 西北生物治疗药物公司 | 诱发改善的或增加的抗肿瘤免疫应答的经最佳活化的树突细胞 |
| WO2017002045A1 (en) | 2015-06-30 | 2017-01-05 | Stemlab, Sa | A viable cell population, method for production and uses thereof |
| US9805601B1 (en) | 2015-08-28 | 2017-10-31 | State Farm Mutual Automobile Insurance Company | Vehicular traffic alerts for avoidance of abnormal traffic conditions |
| US10324463B1 (en) | 2016-01-22 | 2019-06-18 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle operation adjustment based upon route |
| US10395332B1 (en) | 2016-01-22 | 2019-08-27 | State Farm Mutual Automobile Insurance Company | Coordinated autonomous vehicle automatic area scanning |
| US11719545B2 (en) | 2016-01-22 | 2023-08-08 | Hyundai Motor Company | Autonomous vehicle component damage and salvage assessment |
| US10824145B1 (en) | 2016-01-22 | 2020-11-03 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle component maintenance and repair |
| US11441916B1 (en) | 2016-01-22 | 2022-09-13 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle trip routing |
| US10134278B1 (en) | 2016-01-22 | 2018-11-20 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle application |
| US11242051B1 (en) | 2016-01-22 | 2022-02-08 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle action communications |
| KR102038114B1 (ko) * | 2016-02-26 | 2019-10-30 | 주식회사 엘지화학 | 광학 점착제용 (메타)아크릴레이트기 함유 벤조페논의 제조방법 및 광학 점착제 조성물 |
| WO2018160666A1 (en) * | 2017-02-28 | 2018-09-07 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Short-term activated dc1s and methods for their production and use |
| WO2019183924A1 (en) * | 2018-03-30 | 2019-10-03 | Syz Cell Therapy Co. | Improved multiple antigen specific cell therapy methods |
| CA3157004A1 (en) * | 2019-10-07 | 2021-04-15 | Northwest Biotherapeutics, Inc. | In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
| US5366866A (en) * | 1991-07-25 | 1994-11-22 | Duke University | Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB |
| US5227471A (en) * | 1992-01-30 | 1993-07-13 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma |
| US5788963A (en) | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| EA199800272A1 (ru) * | 1995-10-04 | 1998-10-29 | Иммунекс Корпорейшн | Фактор, стимулирующий дендритные клетки |
| US7659119B2 (en) * | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
| ATE428769T1 (de) * | 1997-10-27 | 2009-05-15 | Univ Rockefeller | Methode und zusammensetzung zur herstellung von reifen dendritischen zellen |
| JP2000143534A (ja) * | 1998-11-13 | 2000-05-23 | Asahi Chem Ind Co Ltd | 樹状細胞ワクチン及びその製造方法 |
| JP2000279181A (ja) * | 1999-04-01 | 2000-10-10 | Japan Science & Technology Corp | ヒト樹状細胞の発現遺伝子群 |
| WO2001048154A1 (en) * | 1999-12-28 | 2001-07-05 | Toyoshima, Kumao | Maturation-promoting agent for immature dendritic cells |
| US6247378B1 (en) * | 2000-01-06 | 2001-06-19 | Deere & Company | Operator control device for an infinitely variable transmission |
| JP4841794B2 (ja) * | 2000-05-12 | 2011-12-21 | ノースウエスト バイオセラピューティクス，インコーポレイティド | ヒト樹状細胞による外因性抗原のクラスｉ提示を増加させる方法 |
| JP2004520033A (ja) * | 2001-01-15 | 2004-07-08 | イ・デ・エム・イミュノ−デジネ・モレキュル | 分化拘束された成熟樹状細胞の調製用補助組成物 |
| WO2003010292A2 (en) * | 2001-07-25 | 2003-02-06 | Northwest Biotherapeutics, Inc. | Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors |
-
2002
- 2002-09-06 EP EP10181985.2A patent/EP2322603B1/en not_active Expired - Lifetime
- 2002-09-06 EP EP19202820.7A patent/EP3653055A1/en not_active Withdrawn
- 2002-09-06 WO PCT/US2002/028620 patent/WO2003022215A2/en not_active Ceased
- 2002-09-06 JP JP2003526345A patent/JP2005505270A/ja active Pending
- 2002-09-06 KR KR1020117012621A patent/KR20110081341A/ko not_active Ceased
- 2002-09-06 ES ES10181985T patent/ES2766299T3/es not_active Expired - Lifetime
- 2002-09-06 US US10/488,744 patent/US20050059151A1/en not_active Abandoned
- 2002-09-06 DK DK10181985.2T patent/DK2322603T3/da active
- 2002-09-06 KR KR1020047003386A patent/KR20050027163A/ko not_active Ceased
- 2002-09-06 DK DK02761594.7T patent/DK1441591T3/en active
- 2002-09-06 MX MXPA04002147A patent/MXPA04002147A/es active IP Right Grant
- 2002-09-06 CN CN201210470111.XA patent/CN102973928B/zh not_active Expired - Fee Related
- 2002-09-06 CA CA2459713A patent/CA2459713C/en not_active Expired - Lifetime
- 2002-09-06 PT PT2761594T patent/PT1441591T/pt unknown
- 2002-09-06 PT PT101819852T patent/PT2322603T/pt unknown
- 2002-09-06 NZ NZ531530A patent/NZ531530A/en not_active IP Right Cessation
- 2002-09-06 IL IL16072002A patent/IL160720A0/xx unknown
- 2002-09-06 CN CN028198174A patent/CN1636229B/zh not_active Expired - Fee Related
- 2002-09-06 EP EP02761594.7A patent/EP1441591B1/en not_active Expired - Lifetime
- 2002-09-06 PL PL02372098A patent/PL372098A1/xx not_active Application Discontinuation
- 2002-09-06 KR KR1020147023675A patent/KR101803702B1/ko not_active Expired - Lifetime
- 2002-09-06 ES ES02761594.7T patent/ES2598109T3/es not_active Expired - Lifetime
- 2002-09-06 BR BRPI0212545A patent/BRPI0212545B8/pt not_active IP Right Cessation
-
2004
- 2004-03-03 IL IL160720A patent/IL160720A/en active IP Right Grant
- 2004-03-05 NO NO20040965A patent/NO338147B1/no not_active IP Right Cessation
-
2008
- 2008-05-29 US US12/129,549 patent/US20080254064A1/en not_active Abandoned
- 2008-09-19 AU AU2008221592A patent/AU2008221592B2/en not_active Ceased
-
2011
- 2011-07-04 JP JP2011148711A patent/JP5777956B2/ja not_active Expired - Fee Related
-
2012
- 2012-04-18 IL IL219266A patent/IL219266A/en active IP Right Grant
-
2015
- 2015-03-02 JP JP2015040165A patent/JP6114768B2/ja not_active Expired - Fee Related
- 2015-11-16 NO NO20151562A patent/NO20151562A1/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101803702B1 (ko) | Ｔｈ-1 반응을 위한 단구성 수지상 세포 및 Ｔ 세포를 프라이밍하기 위한 조성물 및 방법 | |
| JP4762887B2 (ja) | 付加的なサイトカインの非存在下でｇｍ−ｃｓｆを用いる単球樹状前駆細胞からの樹状細胞の産生 | |
| US20120244620A1 (en) | Compositions and methods for inducing the activation of immature monocytic dendritic cells | |
| AU2013201707B2 (en) | Compositions and methods for priming monocytic dendritic cells and T cells for Th-1 response | |
| AU2002326846A1 (en) | Compositions and methods for priming monocytic dendritic cells and T cells for Th-1 response | |
| HK1157819A (en) | Compositions and methods for priming monocytic dendritic cells and t cells for th1 response | |
| HK1157819B (en) | Compositions and methods for priming monocytic dendritic cells and t cells for th1 response | |
| HK1079989B (en) | Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response | |
| AU2013206016B2 (en) | Compositions and methods for inducing the activation of immature monocytic dendritic cells | |
| HK1128161A (en) | Compositions and methods for inducing the activation of immature monocytic dendritic cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20110601 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20110630 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20110923 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20130531 Patent event code: PE09021S02D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20140424 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20130531 Comment text: Final Notice of Reason for Refusal Patent event code: PE06011S02I Patent event date: 20110923 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20140725 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20140424 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Appeal identifier: 2014101004667 Request date: 20140725 |
|
| A107 | Divisional application of patent | ||
| AMND | Amendment | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20140825 Application number text: 1020047003386 Filing date: 20040305 |
|
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20140825 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20140725 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20131202 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20130222 Patent event code: PB09011R02I |
|
| B601 | Maintenance of original decision after re-examination before a trial | ||
| PB0601 | Maintenance of original decision after re-examination before a trial | ||
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2014101004667; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20140725 Effective date: 20160623 Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20140725 Effective date: 20160623 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20160623 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20140725 Decision date: 20160623 Appeal identifier: 2014101004667 |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20160822 |
|
| WITB | Written withdrawal of application |